CytoSorbents Q4/FY2025: Revenue $37.1M (+4% YoY), net loss improves to $8.2M; targets H2 2026 cash breakeven

Cytosorbents Corp

Revenue $37.1M (+4% YoY); gross margin 71%. Net loss improved to $8.2M ($0.13/sh) from $20.7M loss.
Adjusted net loss $14.2M ($0.23/sh) flat per share; adjusted EBITDA loss $10.5M improved from $11.5M.
Cash $7.8M at Dec 31, 2025; amended credit facility added $2.5M; workforce reduced 10% in Q4.
Targets cash flow breakeven in H2 2026; ongoing FDA discussions for DrugSorb-ATR De Novo submission (timing TBD).
Direct sales outside Germany +13%, distributor sales +11.4%; Germany sales -10% due to restructuring.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Cytosorbents Corp reported financial results for the quarter and year ended December 31, 2025.

Period: the quarter and year ended December 31, 2025
Result: reported results

Exact text from the filing

On March 25, 2026, CytoSorbents Corporation issued a press release announcing its financial results for the quarter and year ended December 31, 2025.

View on SEC.gov

Browse all earnings releases →

Cytosorbents Corp filing history →

Source: SEC EDGAR

accession 0000929638-26-001150

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.